SCHEMBL4674124

SCHEMBL4674124

O=C(Cc1c[nH]c(Cc2ccccc2)c1)C(=O)c1nc[nH]n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.39
SLC6A2 P23975 1/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
TAAR1 Q96RJ0 1/20 0.35
KDM5A P29375 2/20 0.34
KDM4C Q9H3R0 2/20 0.34
KDM5B Q9UGL1 2/20 0.34
KDM4A O75164 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
NAMPT P43490 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DAO P14920 2/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
CYP2D6 P10635 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676778 0.91 HCAR2 (0.36) HCAR2SLC6A2FNTAFNTBHRH3
SCHEMBL4670917 0.89 HRH4 (0.37) HRH3DAOCYP2D6
SCHEMBL4676578 0.88 DAO (0.34) DAO
SCHEMBL4675442 0.88 HRH3 (0.37) HRH3
SCHEMBL4676475 0.88 DAO (0.34) DAO
SCHEMBL4676724 0.88 HCAR2 (0.44) HCAR2TAAR1DAO
SCHEMBL4677147 0.86 HRH3 (0.40) HRH3TAAR1MEN1KMT2ADAO
SCHEMBL4674803 0.86 KDM5A (0.40) KDM5AKDM5BMEN1KMT2ADAO
SCHEMBL4675270 0.86 KMT2A (0.38) HRH3KMT2ATSHR
SCHEMBL4676973 0.85 DAO (0.35) TAAR1MEN1KMT2ADAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885SLC6A2 513/4885FNTA 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.